Clinical Trial Update: Candesartan's Effects on Alzheimer's Disease And Related Biomarkers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating candesartan for mild cognitive impairment and its effects on Alzheimer's disease biomarkers has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Candesartan (candesartan)

Snippet

Sponsor: Emory University | Conditions: Mild Cognitive Impairment | Phase 2 | Status: COMPLETED | Results posted: 2022-09-29